Innovative treatments and the latest perspectives

January 25, 2023

3 minutes to read

We were unable to process your request. Please try again later. If this issue still occurs, please contact

The Bariatric Society Conference is always the must-attend event for healthcare providers to learn about the latest advances in obesity medicine and to connect with colleagues at the forefront of bariatric treatment.

The Bariatric Society’s 2022 Fall Conference was no different, featuring a lineup packed with expert-led sessions and information on the latest innovations in obesity medicine and treatments.

Data source: 2021 National Health and Nutrition Examination Survey

Its theme was “Overcoming Obesity,” and the conference took place virtually and in person in Anaheim, California, in October. I join hundreds of OMA members and obesity medicine physicians to explore the future of obesity care, with discussions about elevating the patient experience, understanding the controversy around the carbohydrate-insulin model and other topics relevant to obesity medicine today.

While there have been many distinguished sessions and notable speakers, I found Dr. Robert Lustig The keynote, “The Big Picture: NAFLD, Metabolic Syndrome Hot Disease,” to be particularly thought-provoking. In the discussion, Dr. Lustig covered mitochondrial dysfunction, fatty liver, and metabolic disorders in depth. Explain biochemical pathways and describe how to use lifestyle strategies to protect liver function (eg, fructose reduction, total sugar intake, glycemic load and environmental toxins) in a clear and insightful way.

Geetha Kamath

Geetha Kamath

Some other highlights from the OMA Fall Conference included:

Phenotype-genhanced athe essence MEngagement

Dr. Andres Acosta He explained that nearly 40% of adults are obese and the prevalence of the disease is expected to continue to rise. Current obesity treatments are not consistently effective, and the current “one-size-fits-all” approach to obesity care is not working. Dr. Acosta described obesity as a complex and heterogeneous disease with multiple phenotypes that contribute to patient outcomes. Share research that finds that phenotype-directed classification and intervention can lead to weight loss and positive outcomes for obese patients. In addition, obesity phenotypes can be measured with a simple blood test. Expect to hear more about the phenotype-directed lifestyle intervention at the spring conference.

Racknowledgment f Rreating toedema;

Dr. Karen Herbst Share ideas about lipedema and explain why the condition is different from other obesity-related disorders. Lipedema is a disease that is misunderstood and often misdiagnosed as lifestyle obesity, and often confused with lymphedema or fibromyalgia. She shared that the tissue of lipedema has a characteristic distribution of pathological histology that differs from that of non-lipoedema obesity. This is why they require a comprehensive approach to care and treatment that includes:

  • reduce lipedema and non-adipose tissue with bariatric procedures;
  • reducing inflammation through diet, exercise, and nutritional supplements;
  • Treatment of diseases of the veins by vascular surgery or a phlebologist;
  • breaking down fibrous connective tissue structure using approved lymphotherapy; And
  • Focus on mental health with the support of Psychology/Psychiatry.

Lipedema is a complex inflammatory disease that can be painful — both physically and emotionally — and a condition that confuses many healthcare providers.

CBD l acarelessness?

Dr. Jeff sikat He detailed the physiology of the endocannabinoid system (ECS), a vast network of chemical signals and cellular receptors densely packed throughout our brains, nervous system, and body. The ECS regulates vast body functions including appetite, learning, memory, sleep, mood, immune function, inflammation, pain sensation, digestion, and many more. Dr. Sekat shared research on how plant-based cannabinoids and cannabidiol (CBD) affect several metabolic features and lead to weight loss. More studies are being done on the effectiveness of CBD as a treatment for obesity, but the results are certainly interesting.

In addition to the powerful and informative sessions, I also found the discussions on integrating plant-based nutrition, motivational interviewing and innovative behavior change strategies to be very insightful and useful tools in obesity and weight management today.

As an internist, academic consultant practitioner in obesity medicine, and an active member of OMA, I enjoyed the distinguished speakers. It has been an honor to be with so many leaders in obesity medicine and to discuss how we can work together to advocate for the advancement of obesity medicine. I am already looking forward to the 2023 conference in April and continuing these important conversations about obesity medicine, today and in the future.

For more information and to become an OMA member, visit:


  • Acosta A. A phenotype-guided lifestyle intervention for the management of obesity. Filed In: Overcoming Obesity. October 12-16, 2022; Anaheim, California (co-ed meeting).
  • Center for Disease Control. Adult obesity facts. Accessed January 1, 2023.
  • Herbst K. Stepping out of the shadows – recognizing and treating lipedema. Filed In: Overcoming Obesity. October 12-16, 2022; Anaheim, California (co-ed meeting).
  • Lustig R. The big picture – NAFLD, sentinel disorder of the metabolic syndrome (registered). Filed In: Overcoming Obesity. October 12-16, 2022; Anaheim, California (co-ed meeting).
  • Sicat J. CBD for obesity? Our patients ask! Current science review. Filed In: Overcoming Obesity. October 12-16, 2022; Anaheim, California (co-ed meeting).

Leave a Comment